$Affimed NV(AFMD.US)$ NEWS Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology Affimed N.V. (Nasdaq: AFMD) announces the acceptance of the AFM24 clinical abstract at the 2024 ASCO Annual Meeting. The phase 2 study on AFM24 in combination with atezolizumab in patients with EGFR wild-type non-small cell lung cancer has been accepted for poster presentation. The abstract will be available on ASCO's website on May 23, 2024.
$Affimed NV(AFMD.US)$Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
Affimed NV股票討論區
NEWS
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (Nasdaq: AFMD) announces the acceptance of the AFM24 clinical abstract at the 2024 ASCO Annual Meeting. The phase 2 study on AFM24 in combination with atezolizumab in patients with EGFR wild-type non-small cell lung cancer has been accepted for poster presentation. The abstract will be available on ASCO's website on May 23, 2024.
$默沙東(MRK.US)$ x $Immunovant(IMVT.US)$
$禮來(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元製藥公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科學(GILD.US)$ x % $Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施貴寶(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$禮來(LLY.US)$ x $Merus(MRUS.US)$ (partner n...
Dump the Junk
@OBIfromMEM
暫無評論